Gauri Kamath is a freelance journalist and a keen observer of the pharmaceutical and healthcare sectors. Starting as an intern in the Mumbai newsroom of the Business Standard newspaper in 1998, Gauri has closely followed the pharma and healthcare sectors first as a reporter, then a features writer, and later, a blogger, commentator and content specialist. Her former employers include The Economic Times newspaper and Businessworld magazine. In 2012, she left journalism and worked as a content writer for the pharma and healthcare sectors before going back to journalism in early 2021. During this time, she also commentated on the sectors through columns published in Indian Express and moneycontrol.com, among others. Currently, she is Contributing Editor at Shaastra, a science and technology (S&T) magazine published by IIT Madras, where her writing captures developments in drugs, healthcare and medical technology through the prism of S&T.
Click on the links below to read some of Gauri’s writing
J&J’s move to exit talc globally need not raise any fresh concerns – moneycontrol.com
Extension of Covaxin’s shelf life has been mishandled -moneycontrol.com
To the point : The study of exhaled breath could aid the cause of precision medicine -Shaastra
For now a middle ground in Indian healthcare – moneycontrol.com
India must close the tortuous discussions on medical device regulation – moneycontrol.com
Bottle of Lies: What ails India’s drug industry – moneycontrol.com
Lessons we must learn from the FDC fiasco – moneycontrol.com
The J&J hip implant case: On patient safety, India must up its game – moneycontrol.com
Indian healthcare providers need to get serious about infection control – Indian Express
Web drug platforms can only be as good as their partner-chemists on the ground – Indian Express
Untested drug combinations highlight the need to overhaul drug regulation – Indian Express
India’s drug pricing regime pulls off a logic-defying move – Quartz
Why India allows drugs banned elsewhere – Quartz
The ban on a popular diabetes drug shows poor side-effects monitoring – Indian Express
Changing the FDI policy will not improve the availability of essential drugs -Indian Express
The Ranbaxy scandal is more damaging to India’s image than to its prospects – Indian Express
Why the Supreme Court ruling on Glivec won’t bring down drug prices – Sunday ET
Dr Anji Reddy : The man who introduced India to the drug called innovation – Sunday ET
Apothecurry 
All the best Gauri.. Keep writing..
LikeLike
Like the blog title and look! Congrats!
LikeLike
Thanks Meghana, hope you find the content useful as well 😉
LikeLike
Hi Gauri,
Nice to know about you. I may not be able to comment about the contents just now on the topic but i would be interested in knowing more about the health care industry as such and the scenario in mental issues in india and abroad.
The title as meghna said is very appealing. Ills and Pills i am familiar with; i will look forward to the rest! writing about it I suppose is the thrill?
Iam organising a magazine on psychology and neuroscience for the common man to be launched in a month or so. Any ideas and tips about this are welcome!
All the best for your blog
LikeLike
Hi Gauri,
You might remember we had met during the inauguration of Bilcare Research Academy in Pune. You had also written an article on the availability of morphine for cancer patients, we are still working on that.
Though there was high hope among people about the future of clinical research, the field has failed to do as well as expected for a variety of reasons. Good clinical research academies are shutting down (Bilcare Research Academy shut down last years, after a mere four years)
I am now working in Symbiosis International University in the School of Biomedical Sciences. I still do a bit of writing and have recently published an article on morphine in cancer. It is available at:
http://www.ehospice.com/ArticlesList/CancerPainandMorphineinIndia/tabid/3471/ArticleId/1894/language/en-GB/View.aspx#.ULg5-6xwfME.
Do let me know if I can help you in any way.
Dr. Ravindra Ghooi
LikeLike
Hope you are well Dr Ghooi and thank you for connecting via this blog. It’s disappointing that cancer patients are still waging a battle to get their hands on painkilling opiods and I suppose there’s no other way than to keep up the pressure..Thank you for your article and do keep in touch
LikeLike
Gauri,
When Bilcare Research Academy was shut down, it left a number of people high and dry. Many people have not been paid their dues and have faced heavy loss. My own loss is over Rs. 10.75 lacs. I have gone to court against them. I would like to have your advice since you work in the area of pharmaceuticals and also know about finance. Is there any way that jounalists like you can help us?
Regards
Ravi
LikeLike
A very good article on Medical Technology Industry. Views expressed are in fact very true
LikeLike
Hi,
Your blog provides some wonderful insights on healthcare and is an informative read.
I am working with a company called NeedStreet. It is an online healthcare platformed aimed to improve accessibility to healthcare through improved engagement between healthcare providers and patients. Given the skewed doctor-patient ratio, an online platform, coupled with mobile applications powered by NeedStreet, is the best bet to ensure quality care, wherever you may be located.
Do take a look at http://www.needstreet.com. Would love to hear your thoughts.
LikeLike
Its interesting to read the articles. However, as a person working in clinical research I am yet to see any article from anyone regarding the myths that are currently spread in name of research by journals, by companies, NGO’s etc. The myths about cholesterol, statins etc are all there but do not reach the public. We generally hear about the deaths and disabilities in clinical research but the bigger issue lie in conducting it and then how the results get twisted before appearing in respected journals where doctors across the world lap it up. One question I will leave for you – have you seen any negative results of a clinical trials in your life. If you wish to see them read about trial No.329 done more than 10 years ago in Europe and US and read the same one published now again after a lot of effort and legal tussle.
LikeLike
HI Gauri,
Have been a follower of your work from 2001 i think! Glad to see your continued passion for the sector! Will continue to follow your work, goes without saying. Look forward.
LikeLike
Thanks Manan. Hope to keep you interested.
LikeLike